Home > Publications Database > Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer's disease. > print

001     276777
005     20250216000804.0
024 7 _ |a 10.1038/s44321-024-00190-3
|2 doi
024 7 _ |a pmid:39794447
|2 pmid
024 7 _ |a pmc:PMC11822105
|2 pmc
024 7 _ |a 1757-4676
|2 ISSN
024 7 _ |a 1715-4684
|2 ISSN
024 7 _ |a 1757-4684
|2 ISSN
024 7 _ |a altmetric:172971529
|2 altmetric
037 _ _ |a DZNE-2025-00316
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Biel, Davina
|0 0000-0002-2597-1992
|b 0
245 _ _ |a Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer's disease.
260 _ _ |a [London]
|c 2025
|b Nature Publishing Group UK
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1739534424_25078
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In Alzheimer's disease (AD), Aβ triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of Aβ-related p-tau increases which may alter AD trajectories. Here, we assessed whether factors known to alter tau levels in AD modulate the association between fibrillar Aβ and secreted p-tau181 determined in the cerebrospinal fluid (CSF). To assess potentially modulating effects of female sex, younger age, and ApoE4, we included 322 ADNI participants with cross-sectional/longitudinal p-tau181. To determine effects of microglial activation on p-tau181, we included 454 subjects with cross-sectional CSF sTREM2. Running ANCOVAs for nominal and linear regressions for metric variables, we found that women had higher Aβ-related p-tau181 levels. Higher sTREM2 was associated with elevated p-tau181, with stronger associations in women. Similarly, ApoE4 was related to higher p-tau181 levels and faster p-tau181 increases, with stronger effects in female ApoE4 carriers. Our results show that sex alone modulates the Aβ to p-tau axis, where women show higher Aβ-dependent p-tau secretion, potentially driven by elevated sTREM2-related microglial activation and stronger effects of ApoE4 carriership in women.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s Disease
|2 Other
650 _ 7 |a Microglia
|2 Other
650 _ 7 |a Sex Differences
|2 Other
650 _ 7 |a p-tau
|2 Other
650 _ 7 |a sTREM2
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a TREM2 protein, human
|2 NLM Chemicals
650 _ 7 |a Membrane Glycoproteins
|2 NLM Chemicals
650 _ 7 |a Receptors, Immunologic
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Apolipoprotein E4
|2 NLM Chemicals
650 _ 7 |a MAPT protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Membrane Glycoproteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Membrane Glycoproteins: metabolism
|2 MeSH
650 _ 2 |a Receptors, Immunologic: metabolism
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Sex Factors
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Apolipoprotein E4: genetics
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
700 1 _ |a Suarez-Calvet, Marc
|0 P:(DE-2719)2811727
|b 1
700 1 _ |a Dewenter, Anna
|b 2
700 1 _ |a Steward, Anna
|0 0000-0002-8438-3760
|b 3
700 1 _ |a Roemer, Sebastian N
|0 0000-0003-3423-457X
|b 4
700 1 _ |a Dehsarvi, Amir
|0 0000-0001-7116-9741
|b 5
700 1 _ |a Zhu, Zeyu
|b 6
700 1 _ |a Pescoller, Julia
|b 7
700 1 _ |a Frontzkowski, Lukas
|b 8
700 1 _ |a Kreuzer, Annika
|b 9
700 1 _ |a Haass, Christian
|0 P:(DE-2719)2202037
|b 10
700 1 _ |a Schöll, Michael
|0 0000-0001-7800-1781
|b 11
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 12
|e Last author
|u dzne
700 1 _ |a Franzmeier, Nicolai
|0 0000-0001-9736-2283
|b 13
773 _ _ |a 10.1038/s44321-024-00190-3
|g Vol. 17, no. 2, p. 235 - 248
|0 PERI:(DE-600)2485479-7
|n 2
|p 235 - 248
|t EMBO molecular medicine
|v 17
|y 2025
|x 1757-4676
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276777/files/DZNE-2025-00316.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276777/files/DZNE-2025-00316.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276777
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2202037
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-28
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO MOL MED : 2022
|d 2024-12-28
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EMBO MOL MED : 2022
|d 2024-12-28
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-02-14T13:51:27Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-02-14T13:51:27Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review, Double anonymous peer review
|d 2024-02-14T13:51:27Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21